BIOS Community
Published in

BIOS Community

BIOS Ventures: Behind the Scenes of TechBio’s Leading VC Firms

BIOS: Nucleus of Life Science Innovation 🚀

JOBS

CONTENT & COMMUNITY

INVEST

By:

Alix Ventures: Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health

Calling All Innovators Click to Reach Out 🚀

Overview 💥

We’re excited to announce the launch of BIOS Venture Series — a new YouTube series going behind the scenes with the world’s leading TechBio Venture Capital Firms🔬

With the rise of TechBio — a melding of technology and biology — the life science sector is experiencing unprecedented and accelerating innovation. We believe this change is leading to some of the most impactful breakthroughs in decades, ushering in the century of biology.

BIOS Ventures provides a platform for leading VCs to discuss their approach to driving scientific innovation. Each episode will feature top investors providing insight into their investment principles, portfolio dynamics, value adds / firm differentiators, industry trends, , future of Life Sciences, and so much more :)

We’ll dive deep into the similarities and differences between venture creation and venture investment, consider the rapid growth of life science investment in recent years, and share the storied history of some of the most successful Life Science VC firms.

Each episode sheds light on the journey of these VCs and their breakout investments. We highlight their firm origin stories, discover how they overcome major challenges, and explore the great beyond of what comes next for their funds.

This is an amazing opportunity for entrepreneurs, researchers, and Pharma to contextualize the financing side of venture & learn about how top VCs approach TechBio investing.

Guests on the Show 🧬

Each episode of BIOS Ventures stars our guests and our guides into the VC industry some of the leading TechBio VCs who make up the top General Partners, Partners, & Principals in the industry. Such as: 8VC, a16z, ARTIS Ventures, Lux Capital, & more.

Topics We’ll Explore 🔬

Eager to understand how leading VC firms view startup collaboration and investment, what resources they offer, and where you can find information relevant for your entrepreneurial journey? Each episode will provide an opportunity to dive deeper into the journey of some of the top VC firms.

A few firms we’ve hosted & will host…

Checkout Our Episodes…

Guests: D.A. Wallach & Tim Wright @ Time BioVentures

D.A. Wallach is a venture capital investor and an acclaimed recording artist who Fast Company named one of the 100 Most Creative People in Business. While an undergraduate at Harvard, D.A. studied with professor Henry Louis Gates, Jr., and received the Andrew Ramroop and Alain Locke prizes as the top graduate in his department. Prior to leaving school, Kanye West and Pharrell Williams discovered D.A.’s band, Chester French, and Williams signed the group to Interscope Records, where they released two full-length albums. He has toured with Lady Gaga, Weezer, and Blink 182, performed on TV Shows including Jimmy Kimmel Live and Late Night with Jimmy Fallon, and appeared in Rolling Stone and Vogue.

In 2011, D.A. stopped touring in order to focus on his other passion, investing. He has since built a parallel career as a venture capitalist, backing a series of industry-defining technology companies including Spotify, SpaceX, Ripple, The Boring Company, and Memphis Meats. Since 2015, D.A. has focused on biotechnology and healthcare, seeking to reinvent medicine through breakthrough start-ups like Beam, Glympse, Doctor on Demand, Devoted Health, and Neuralink. As co-founder and General Partner of Time BioVentures, he brings this experience to a new generation of talented entrepreneurs in the life sciences.

Outside of work, D.A. appeared as an actor in the film La La Land, which received 14 Academy Award nominations. He publishes essays on a range of topics on his website www.dawallach.com, and is the co-founder of the non-profit Franca Fund for preventive genomics, an advisory board member of No Patient Left Behind, and a member of the Board of Trustees of the Santa Fe Institute.

Tim Wright, is a general partner of Time BioVentures and one of the world’s most accomplished drug developers. In a career spanning academic research, clinical medicine, big pharma, and biotech, Dr. Wright has guided the development of twenty breakthrough drugs now on the market, including 10 “blockbusters” that have each sold over $1 billion USD annually. He brings to Time BioVentures’ portfolio a deep expertise in translational science and commercialization, as well as an understanding of the dynamics of the private and public biotech markets.

Wright began his career as a physician-scientist, completing his medical degree, rheumatology clinical fellowship, and postdocs in molecular biology and immunology at Johns Hopkins University. He subsequently served on the faculty at Hopkins, and then as a tenured Associate Professor and Division Chief at the University of Pittsburgh School of Medicine, where he ran an NIH-funded research laboratory.

Following a successful leap from academia to industry, Wright spent three years at Pfizer in Research and Exploratory Development. He then moved to Novartis Pharmaceuticals where he held roles of increasing responsibility, including Deputy Head of Translational Research, Global Head of Translational Medicine, Global Head of Translational Sciences and finally, Global Head of Pharma Development.

In 2015, Wright moved to California and immersed himself in the fast-paced world of start-up biotech, first as Executive Vice President at CALIBR (affiliated with Scripps Research), and then as Chief R&D officer at Regulus Therapeutics. Dr. Wright serves as a scientific advisor to the Bill and Melinda Gates Foundation and the Leonard Schaeffer Center for Health Policy and Economics at USC. He has also held Board of Directors roles at Schrödinger and CureVac, two prominent public biotech companies.

Learn More @ https://www.timebioventures.com

Guest: Jacob Vogelstein — Co-Founder @ Catalio Capital

Jacob Vogelstein is Co-Founder & Managing Partner @ Catalio Capital Management. He makes investments in breakthrough biomedical technology companies founded by world-renowned scientist entrepreneurs. Previously, he was a General Partner at Camden Partners Holdings, LLC, a private equity firm.

He currently serves on the Board of Directors of Cage Pharmaceuticals, Entos, Haystack Oncology, manaT bio, amongst others

Prior to joining Camden, Jacob was a founding partner of the seed-stage venture capital firm Gamma 3, LLC, and a Program Manager at the Intelligence Advanced Research Projects Activity, where he made investments in high-risk, high-reward research to benefit the US Intelligence Community. Earlier in his career, Jacob served on the faculty at Johns Hopkins University, at both the Applied Physics Laboratory and the Whiting School of Engineering.

Jacob has received widespread recognition for his innovative work in biomedical engineering over the past decade. In 2017, he was awarded the Presidential Early Career Award in Science and Engineering, which is the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their careers. He has been an invited speaker for diverse audiences ranging from BBC News to President Obama’s Council of Advisors on Science and Technology, has authored over 50 peer-reviewed publications, and has multiple patents in the fields of neuroprosthetics and brain-machine interfaces.

Jacob earned a BSc. degree in Bio-Electrical Engineering from Brown University and a Ph.D. degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.

Learn More @ https://www.cataliocapital.com

📣 If you enjoyed this post please clap 👏 & comment 💬 to let us know

Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.

Join BIOS Community 🎉

Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, & invite-only events…

Apply to Join — Membership Application

For More Interesting Content 💭

🧬 PodcastStream Full Episodes

🧪 YouTube Watch Videos

🩺 Twitter Explore Feed

🦠 LinkedInRead Posts

Subscribe to BIOS Newsletter for special content: Click Here 🔥

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store